Imunon company info

What does Imunon do?
Imunon (NASDAQ:IMNN) specializes in pioneering the development of novel immunotherapies aimed at treating a variety of cancers. With a focus on leveraging cutting-edge scientific research, Imunon strives to unlock new pathways in immune modulation to combat malignancies. The company's robust project pipeline is centered on advancing treatments that harness the body's own immune system to fight cancer more effectively. Imunon is firmly committed to its mission of bringing groundbreaking cancer therapies from the lab to the clinic, thereby aiming to improve patient outcomes and enhance quality of life for those battling cancer.
Imunon company media
Company Snapshot

Is Imunon a public or private company?

key
Ownership
Public

How many people does Imunon employ?

people
Employees
33

What sector is Imunon in?

pie chart
Sector
Health Care

Where is the head office for Imunon?

location pin
Head Office
New Jersey, United States

What year was Imunon founded?

founded flag
Year Founded
1982
What does Imunon specialise in?
/Pharmaceutical Research /Biotechnology Innovation /Immunotherapy Development /Vaccine Production /Clinical Trials /Healthcare Solutions

What are the products and/or services of Imunon?

Overview of Imunon offerings
LEAPS technology platform for vaccine development, focusing on autoimmune diseases and cancer.
COVID-19 vaccine candidates, utilizing LEAPS for coronavirus variants.
Therapeutic vaccines for Rheumatoid Arthritis, leveraging LEAPS platform.
HIV vaccine development program, applying LEAPS technology for prevention.
Inflammatory diseases treatment solutions, targeting conditions like Crohn's disease.
Collaborations with academic and industry partners for advancing vaccine research and development.

Who is in the executive team of Imunon?

Imunon leadership team
  • Mr. Michael H. Tardugno
    Mr. Michael H. Tardugno
    Executive Chairman
  • Mr. Jeffrey W. Church CPA
    Mr. Jeffrey W. Church CPA
    CFO, Executive VP & Corporate Secretary
  • Dr. Khursheed  Anwer M.B.A., Ph.D.
    Dr. Khursheed Anwer M.B.A., Ph.D.
    Executive VP & Chief Scientific Officer
  • Mr. Timothy J. Tumminello CPA
    Mr. Timothy J. Tumminello CPA
    Chief Accounting Officer & Controller
  • Ms. Marianne M. Lambertson
    Ms. Marianne M. Lambertson
    Vice President of Communications & Investor Relations
  • Dr. Sebastien  Hazard M.D.
    Dr. Sebastien Hazard M.D.
    Executive VP & Chief Medical Officer